Abstract: It is universally believed that chemotherapy is one of the most effective approaches to deal with cancer at present, nevertheless most anticancer drugs adopted in chemotherapy show strong side effects and multidrug resistance. The majority of the side effects are derived from the inability of anticancer drugs to distinguish between tumor tissues and normal tissues. Polymer nanoparticles can be used as drug carriers to embed anti-cancer drugs, which endow drugs with certain selectivity and can reduce toxicity and side effects of drugs on normal tissues owing to their targeted and intelligent functions. Besides, the drug delivery system made of polymer nanoparticles exhibit advantages of low toxicity, high efficiency and sustained release, etc. A variety of high-molecular carriers has been prepared for delivery of anticancer drugs, for the sake of attenuating the side effects caused by anticancer drugs and relieving drug resistance. Pluronic is a kind of synthetic amphiphilic polymer material, showing its superiority in no toxicity, favorable biocompatibility, no immunogenicity, anti-tumor multidrug resistance and feasibility for chemical modification. Therefore, the study of polymer nanoparticles containing Pluronic as drug carriers has aroused numerous interests in the field of anticancer drugs delivery. The polymer nanoparticles formed by Plurnoics are small in size and can be passively targeted to tumor tissues, thus reducing toxicity of drugs to normal tissues. In addition to the nanoscale particles size, the nanoparticles formed by chemically modified Pluronic possess many other superior properties. Pluronic modified by antibody, targeting small molecules and biotin is conductive to realize the active targeting to tumor tissues of carriers. The modification of the magnetic material endows Pluronic nanoparticles with magnetism, which enables the encapsulated drugs localize and aggregate into the tumor tissue under a certain magnetic intensity. The introduction of some pH sensitive and redox materials have equipped Pluronic nanoparticles with pH and oxidation-reduction sensitivities. The prepared intelligent drug carrier encapsulated anticancer drugs can respond to the environmental variations of tumor tissues and stimulate drug release. Meanwhile, double-targeting drug carrier containing Pluronic have been also prepared successfully, which presents better targeting effect than single-targeting one. The development of targeted and intelligent drug carriers in the future can further improve the therapeutic effect of drugs. This article offers a summary of the research status of polymer nanoparticles containing Pluronic in targeting and intelligent drug delivery systems, the former includes active targeting, passive targeting and physical targeting, the latter includes pH-sensitive and reduction-sensitive systems. Emphasis is put on the nano-properties, drug release, targeting and stimulation response properties of carriers. We would like to provide new ideas for the delivery of drugs with good efficacy, but poor solubility and side effects, and provide some reference and basis for the wide application of Pluronic in biomedical material fields.
陈道鸽, 熊向源, 龚妍春, 李资玲, 李玉萍. 含Pluronic高分子纳米粒子在药物释放体系的研究现状[J]. 材料导报, 2019, 33(3): 517-521.
CHEN Daoge, XIONG Xiangyuan, GONG Yanchun, LI Ziling, LI Yuping. Research and Application of Polymeric Nanoparticles Containing Pluronic in Drug Release System: a Review. Materials Reports, 2019, 33(3): 517-521.
1 Du Z Z, Zhang Y, Xu H, et al. Journal of Materials Chemistry B,2015,3(18),3685. 2 Zhang M J, Jing S S, Zhang J, et al. Journal of Materials Chemistry B,2017,5(21),3970. 3 Pitto-Barry A, Barry N P E. Polymer Chemistry,2014,5(10),3291. 4 Oerlemans C, Bult W, Bos M, et al. Pharmaceutical Research,2010,27,2569. 5 Wang Y, Liu E G, Sun X Y, et al. Polymer Chemistry,2013,4(10),2958. 6 Chen G J, Su Y Z, Hsu C, et al. Journal of Materials Chemistry B,2014,2(34),5666. 7 She W C, Pan D, Luo K, et al. Journal of Biomedical Nanotechnology,2015,11(6),964. 8 Song H, He R, Wang K, et al. Biomaterials,2010,31(8),2302. 9 Choi W I, Lee J H, Kim J Y, et al. Nanomedicine,2015,11(2),359. 10 Tavano L, Muzzalupo R, Mauro L, et al. Langmuir,2013,29(41),12638. 11 Tavano L, Mauro L, Naimo GD, et al. Langmuir,2016,32(35),8926. 12 Huang Y K, Liu W, Gao F, et al. International Journal of Nanomedicine,2016,11,1629. 13 Niu J X, Wang A D, Ke Z C,et al. Journal of Drug Target,2014,22(8),712. 14 Luo Y Y, Xiong X Y, Cheng F, et al. International Journal of Biological Macromolecules,2017,105,711. 15 Li Y M, Zhou Y, De B, et al. Journal of Microencapsulation,2014,31(8),805. 16 Nguyen D H, Bae J W, Choi J H, et al. Journal of Bioactive and Compa-tible Polymers,2013,28(4),341. 17 Wang H, Agarwal P, Zhao S T, et al. Biomaterials,2015,72,74. 18 Wang F,Li L,Liu B,et al. Biomedicine & Pharmacotherapy,2017,86,595. 19 Xiong X Y, Gong Y C, Li Z L, et al. Journal of Biomaterials Science, Polymer Edition,2011,22(12),1607. 20 Xiong X Y, Guo L, Gong Y C, et al. European Journal of Pharmaceutical Sciences,2012,46(5),537. 21 Wang N, Guan Y P, Yang L R, et al. Journal of Colloid Interface Science,2013,395,50. 22 Huang C, Tang Z M, Zhou Y B, et al. International Journal of Pharmaceutics,2012,429(1-2),113. 23 Dehvari K, Chen Y, Tsai Y-H, et al. Journal of Biomedical Nanotechno-logy,2016,12(9),1734. 24 Chen Y Z, Zhang W, Gu J J, et al. International Journal of Pharmaceutics,2013,452(1-2),421. 25 Wei Z, Yuan S, Chen Y Z, et al. European Journal of Pharmaceutics and Biopharmaceutics,2010,75(3),341. 26 Kim J Y, Choi W I, Kim Y H, et al. Journal of Controlled Release,2010,147(1),109. 27 Lee J H, Sahu A, Jang C, et al. Journal of Controlled Release,2015,209,219. 28 Morral-Ruíz G, Melgar-Lesmes P, López-Vicente A, et al. Nano Research,2015,8(5),1729. 29 Russo A, Pellosi D S, Pagliara V, et al. International Journal of Pharmaceutics,2016,511(1),127. 30 Ren Y, Zhang H, Chen B, et al. International Journal of Nanomedicine,2012,7,2261. 31 Singh N, Jenkins G J H, Asadi R, et al. Nano Reviews,2010,1(1),5358. 32 Chen Y, Zhang W, Huang Y, et al. International Journal of Pharmaceutics,2015,488(1-2),44. 33 Kabanov A V, Batrakova E V, Alakhov V Y. Journal of Controlled Release,2002,82(2-3),189. 34 Fox M E, Szoka F C, Frechet J M. Accounts of Chemical Research,2009,42(8),1141. 35 Nguyen D H, Joung Y K, Choi J H, et al. Biomedical Materials,2011,6(5),055004. 36 Cai X Q, Liu M R, Zhang C, et al. Colloids and Surfaces B: Biointerfa-ces,2016,142,114. 37 Li Y P, Xiao K, Luo J T, et al. Biomaterials,2011,32(27),6633. 38 Tang L Y, Wang Y C, Li Y, et al. Bioconjugate Chemistry,2009,20(6),1095. 39 Tao Y H, Han J F, Ye C T, et al. Journal of Materials Chemistry,2012,22(36),18864. 40 Zhao X J, Chen Q, Li Y S, et al. European Journal of Pharmaceutics and Biopharmaceutics,2015,93,27. 41 Choo E S G, Yu B, Xue J. Journal of Colloid and Interface Science,2011,358(2),462. 42 Fang X B, Zhang J M, Xie X, et al. International Journal of Pharmaceutics,2016,502(1-2),28. 43 Liang Y C, Su Z H, Yao Y, et al. Materials,2015,8(2),379. 44 Ma Y K, Fan X H, Li L B. Carbohydrate Polymers,2016,137,19.
渝公网安备50019002502923号 版权所有：《材料导报》编辑部
2019, Vol. 33 
